1. Home
  2. SWIM vs ESPR Comparison

SWIM vs ESPR Comparison

Compare SWIM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Latham Group Inc.

SWIM

Latham Group Inc.

HOLD

Current Price

$5.31

Market Cap

769.9M

Sector

Industrials

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$2.75

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWIM
ESPR
Founded
1956
2008
Country
United States
United States
Employees
N/A
294
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
769.9M
731.9M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
SWIM
ESPR
Price
$5.31
$2.75
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$7.33
$7.60
AVG Volume (30 Days)
1.0M
4.8M
Earning Date
03-03-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
160.00
60.71
EPS
0.09
N/A
Revenue
$545,912,000.00
$403,135,000.00
Revenue This Year
$10.85
$2.92
Revenue Next Year
$6.12
N/A
P/E Ratio
$61.00
N/A
Revenue Growth
7.35
21.31
52 Week Low
$4.56
$0.73
52 Week High
$8.97
$4.18

Technical Indicators

Market Signals
Indicator
SWIM
ESPR
Relative Strength Index (RSI) 32.98 45.18
Support Level N/A $2.66
Resistance Level $6.97 $3.02
Average True Range (ATR) 0.27 0.18
MACD -0.06 0.04
Stochastic Oscillator 2.45 63.00

Price Performance

Historical Comparison
SWIM
ESPR

About SWIM Latham Group Inc.

Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: